Dr. Leinwand is a Professor of Molecular, Cellular, and Developmental Biology and Chief Scientific Officer of the Colorado Initiative in Molecular Biotechnology at the University of Colorado, Boulder. She received her Bachelor’s degree from Cornell University, her Ph.D. from Yale University and did post-doctoral training at Rockefeller University. She joined the faculty at Albert Einstein College of Medicine in New York and remained there until moving to Colorado. While at Albert Einstein she became a Full Professor and was Director of the Cardiovascular Research Center. Once in Colorado, along with Michael Bristow and Eric Olson, she co-founded Myogen, Inc. which was recently sold to Gilead Pharmaceuticals. The interests of Dr. Leinwand’s laboratory are the genetics and molecular physiology of inherited diseases of the heart and how gender and diet modify the heart. The study of these diseases and physiological processes has required multidisciplinary approaches, involving molecular biology, mouse genetics, mouse cardiac physiology, and the analysis of human tissues. To accomplish this, Dr. Leinwand ha sdeveloped a highly collaborative group, bringing together specialized basic scientists and clinical cardiologists. Herlaboratory’s efforts are well funded and her teaching is recognized by funding from the Howard Hughes Medical Institute’s Professor Program. She is also the Program Director of the HHMI program, the Biological Sciences Initiative, which supports undergraduate research, K-12 outreach and educational programs for high school teachers.